This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months) and COPD persons without frequent exacerbations to determine acute exacerbation of COPD (AECOPD)-associated dysfunction in a) cytokines and immune effector cells of the nasal mucosa and b) viral replication. The investigators hypothesize that: 1) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate altered mucosal immune responses to LAIV exposure, and 2) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate increased markers of influenza viral replication after LAIV exposure.

开始日期2022-10-03

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

NCT04110366

/ CompletedN/AIIT

Kinetics of Mucosal and Systemic Immune Responses to Intranasal Live Attenuated Influenza Vaccine (LAIV)

Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK. It is also licensed to be given to adults up to the age of 49 years in the USA. The systems biology of the human blood response to influenza vaccines has been studied in great detail, but there is a paramount need to study innate and specific, soluble and cellular immune responses at the nasal mucosal site of influenza infection. In this way this study aims to determine correlates of efficacy and vaccine take in serum and nasal mucosal lining fluid (MLF).

开始日期2018-06-14

申办/合作机构

Imperial College Healthcare NHS Trust

EUCTR2016-003138-26-NL

/ Unknown status临床4期IIT

Influenza vaccination in patients with Myasthenia Gravis - Influenza vaccine in Myasthenia Gravis

开始日期2016-10-04

申办/合作机构

Leids Universitair Medisch Centrum

100 项与 Influenza vaccine live(MedImmune LLC) 相关的临床结果

登录后查看更多信息

100 项与 Influenza vaccine live(MedImmune LLC) 相关的转化医学

登录后查看更多信息

100 项与 Influenza vaccine live(MedImmune LLC) 相关的专利（医药）

登录后查看更多信息

987

项与 Influenza vaccine live(MedImmune LLC) 相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Exploring nurses’ experiences with a school-located influenza vaccination program: A qualitative study in the region of Murcia, Spain

Article

作者: Perez Martin, Jaime ; Robles Mañueco, Marta ; Martínez Ruiz, Marina ; Zornoza Moreno, Matilde

A cross-sectional qualitative pilot study was designed to assess the nurses' perspectives regarding a school-located influenza vaccination pilot program. The program was developed during the 2022-2023 season in the Region of Murcia (an autonomous community of Spain) targeting the 3- to 4-year population in 24 public schools, using the intranasal Fluenz® Tetra vaccine. School nurses unanimously recognized their professional role not only in administering the vaccine, but also in the development and implementation of general aspects of the pilot program and reported that the experience was very positive. Nursing professionals should be fully involved in providing information to parents about the main aspects of influenza infection and benefits of having their children vaccinated against seasonal influenza. Nurses also advocated that the flu vaccination for children should begin at the same time as vaccination for adults, with vaccination planning completely integrated into the school schedule.Practice implications: The study results could guide healthcare authorities in facilitating the implementation of school-located influenza vaccination programs and increase immunization of preschool children against flu.

2025-09-01·Mayo Clinic Proceedings: Digital Health

Using Social Media to Combat Influenza Vaccine Misinformation and Improve Uptake: A Social Media Campaign and Repeated Cross-sectional Survey Analysis

Article

作者: Steier, Jessica B

Objective:

To combat influenza (flu)-vaccine misinformation and improve vaccine uptake using social media.

Patients and Methods:

Unbiased Science used an online survey to identify flu vaccine-hesitant demographic groups and their specific objections to vaccination. Targeted educational content was then created and deployed through a variety of media formats, including podcasts, newsletters, reels, and infographics. A postcampaign survey determined the proportion of individuals who changed their minds about vaccination as a result of the educational content. The study was conducted between October 28, 2022 and February 7, 2023.

Results:

In 3626 precampaign surveys, 187 individuals (5.1%) reported being unvaccinated and not planning to get the flu vaccine (the unvaccinated group). Multivariable analysis showed that geographic region (Northeast and Southeast), gender identity (male and other), race-ethnicity (non-Hispanic Black, and non-Hispanic other), and education level (high-school or less and some college) were independently associated with being unvaccinated. The main reasons were needlephobia, dismissal of flu severity, and concerns about vaccine components, multiple vaccines, and side effects. In 838 postcampaign surveys, 39 individuals (4.7%) indicated changing their mind about vaccination: of these, 27 (69.2%) said they were more likely to get vaccinated and 22 (56.4%) had gotten vaccinated. Twenty individuals (51.3%) said they changed their mind at least in part because of the targeted educational content.

Conclusion:

Social media has the potential to change attitudes and behaviors around vaccination. When science messaging is deployed across several platforms and targeted to key demographic characteristics, it has the ability to combat misinformation and influence vaccine uptake.

2025-08-01·PUBLIC HEALTH

A jab is not a vaccine; it's a ‘shot’

Article

作者: Demjén, Zsófia ; Elena Semino ; Gleave, Richard

OBJECTIVES:

Previous work identified a new type of vaccine scepticism on social media centred around questioning the status of the COVID-19 vaccine as a vaccine, partly by contrasting 'vaccine' with 'shot'. This study aimed to investigate whether this scepticism also manifests with a contrast between 'vaccine' and 'jab', a term more commonly used in parts of the United Kingdom.

STUDY DESIGN:

Corpus-based discourse analysis.

METHODS:

Using a corpus of 261,203 tweets focused on the MMR vaccine, we used collocations and concordancing to identify instances of 'jab' and its variants that co-occurred with references to COVID-19. We qualitatively examined 50 % of the relevant tweets (n = 319) to identify any that undermined the status of the COVID-19 vaccines as vaccines.

RESULTS:

18 % (n = 59) of the examined tweets used 'jab' to undermine the status of the COVID-19 vaccine as a vaccine. A 'jab' was seen as inferior to a 'vaccine' on the basis that it did not prevent infection. Although this contrast mostly focused on the COVID-19 vaccine, some tweets also referenced the flu vaccine as another example that is therefore not a vaccine.

CONCLUSIONS:

Our analysis showed that 'jab' and its variants are seen to indicate an intervention that is inferior to vaccination, similarly to 'shot' in previous work. This evidence suggests that 'jab' and its variants are best avoided in public health campaigns designed to encourage uptake of vaccinations in the UK.

117

项与 Influenza vaccine live(MedImmune LLC) 相关的新闻（医药）

2025-04-08

·astrazeneca.com

AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025

AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria, from 11-15 April 2025. With 13 abstracts, including two oral presentations and two late-breaking poster presentations, the Company will highlight progress in advancing novel immunisations against bacterial and viral infectious diseases and share real-world evidence showing the burden of respiratory viral infections and the continued need for protection. Benjamin Moutier, Senior Vice President, Vaccines & Immune Therapies, AstraZeneca said: “AstraZeneca is building an innovative portfolio of antibodies and vaccines to tackle two of the top global public health threats – serious bacterial infections and respiratory viral infections. At ESCMID, we’ll share data on three novel monoclonal antibodies targeting high-priority pathogens, highlighting our ambition to redefine care for serious bacterial infections. In addition, we will present 20 years of effectiveness data for Fluenz/FluMist, as well as real-world data highlighting the ongoing burden of RSV and hMPV, two leading causes of respiratory illnesses.” Advancing potential new options for serious bacterial infection prevention and treatment Serious bacterial infections pose significant and growing threats to global health, linked to an estimated 7.7 million deaths a year globally, leading to increasing morbidity and mortality for patients and a substantial burden on health systems.1 At ESCMID, the Company will share preclinical data on investigational monoclonal antibodies (mAbs) targeting three of the top five pathogens identified as urgent risks by the Centers for Disease Control and Prevention: Staphylococcus aureus (S. aureus): Oral presentation on in vivo expression of an mRNA-encoded multi-mechanistic mAb combination against S. aureus. There are millions of methicillin-resistant S. aureus (MRSA) infections annually worldwide, and MRSA is resistant to many types of antibiotics, making treatment highly complex. A pathogen-specific treatment strategy with mAbs targeting some S. aureus virulence factors represents an alternative to broad spectrum antibiotics.2 Pseudomonas aeruginosa (P. aeruginosa): Preclinical data showing that gremubamab, an anti-P. aeruginosa bispecific human mAb, may enhance neutrophil-mediated killing of P. aeruginosa in bronchiectasis patients. P. aeruginosa is a pathogen that colonizes one-third of patients with bronchiectasis, a chronic lung condition impacting about one million people globally and drives significant disease morbidity and mortality.3 Klebsiella pneumoniae (K. pneumoniae): Research on the development and characterisation of bispecific antibodies that protect against bacteraemia and pneumonia from the major serotypes of antibiotic-resistant K. pneumoniae in mouse models. Infections caused by K. pneumoniae are responsible for more than 700,000 yearly deaths worldwide.4 Real-world data examining the impact of respiratory infections AstraZeneca is presenting 20 years of real-world data on Fluenz/FluMist (live attenuated influenza vaccines, LAIV), recently approved in the U.S. as the only vaccine for self- or caregiver administration for the prevention of influenza, demonstrating long-term effectiveness comparable to that of inactivated (IIV) influenza vaccines in children.5 The Company will also present two late-breaking posters featuring real-world studies in patients with haematological malignancies who are highly susceptible to severe respiratory infections. The studies show that outcomes from human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) were similar to those from influenza and COVID-19, highlighting the need for development of novel options for preventing disease caused by hMPV and RSV.6,7 Retrospective analyses from Valencia, Spain, where there is systematic testing for multiple respiratory viruses, highlight the impact of RSV and influenza on severe disease and mortality in older adults throughout the COVID-19 pandemic, and suggest a potentially greater proportion of mechanical ventilation use and in-hospital death from RSV than influenza in adolescents and adults.8,9 Additional real-world data from France highlight the extensive healthcare resource utilisation due to hMPV and RSV and underline the need for routine testing for hMPV to accurately assess its true burden.10 Additionally, data being presented by our partner, Sanofi, confirm the significant public health impact and real-world effectiveness of Beyfortus in reducing RSV disease and hospitalisations in infants.11 Furthering Research in COVID-19 Prevention Data on AZD6563, an investigational novel COVID-19 mRNA vaccine-like particle (VLP) vaccine, demonstrating that a low dose may elicit equivalent cell-mediated immunity to a licensed mRNA vaccine will also be shared.12 Additionally, data will be presented increasing confidence in a SARS-CoV-2 variant-agnostic threshold which could be used as a surrogate endpoint for benchmarking expected efficacy of novel mAbs for the prevention of COVID-19 against emerging variants.13 Key AstraZeneca presentations during ESCMID 2025 Abstract Title Presentation Details Abstract Title Early Science: Serious Bacterial Infections and Respiratory Viral Infections Abstract Title In vivo expression of an mRNA encoded multi-mechanistic mAb combination against Staphylococcus aureus and protection in disease model Presentation Details Oral Presentation Session Title: Around the Lab in 80 Ways: A Journey Through Innovative Therapeutics Date: Saturday 12 April 2025 Time: 11 AM – 12 PM CEST Location: Hall 13 Abstract Title Low dose of a novel SARS-COV-2 mRNA VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine Presentation Details Poster Presentation Session Title: COVID-19 Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Bronchiectasis Patient Neutrophil-Mediated Killing Of Pseudomonas aeruginosa Presentation Details Poster Presentation Session Title: Drug Discovery and New Compounds Mechanisms of Action & Spectrum, Preclinical Data & Basic Pharmacology Date: Sunday 13 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Broad coverage of antibiotic-resistant Klebsiella pneumoniae by multi-specific antibodies against the lipopolysaccharide O-antigen Presentation Details Poster Presentation Session Title: Drug Discovery and New Compounds Mechanisms of Action & Spectrum, Preclinical Data & Basic Pharmacology Date: Sunday 13 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Real-World Evidence: Respiratory Infections Abstract Title Comparative outcomes of hMPV, influenza, and SARS-CoV-2 infections in haematologic malignancy patients: A matched cohort analysis Presentation Details Late-Breaking Poster Presentation Session Title: Outbreaks and Public Health Emergencies Date: Tuesday 15 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Matched cohort study comparing the impact of RSV, influenza, and SARS-CoV-2 infections in patients with haematological malignancies Presentation Details Late-Breaking Poster Presentation Session Title: Outbreaks and Public Health Emergencies Date: Tuesday 15 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Similar proportions and temporal patterns of influenza, RSV, and hMPV among ESKD patients tested between 2020-2023 Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Characterization of hMPV and RSV cases in the French national hospital claims database during the 2022-2023 season Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Shifting viral landscapes: the impact of SARS-CoV-2 on hospitalization, ICU admission, and mortality in respiratory infections among older adults in Valencia, Spain Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Respiratory syncytial virus (RSV)-associated hospitalised influenza-like illness (ILI) and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015-2019/2020: the VALSARI study Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title Real-world effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines in children: a systematic literature review (SLR) and network meta-analysis (NMA) Presentation Details Poster Presentation Session Title: Influenza and Respiratory Viruses Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Abstract Title COVID-19 mAbs Abstract Title Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial Presentation Details Oral Presentation Session Title: New developments in prophylaxis and treatment of COVID-19 Date: Saturday 12 April 2025 Time: 11:00 Location: Hall 6 Abstract Title A threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19 enabling rapid development for future SARS-CoV-2 variants Presentation Details Poster Presentation Session Title: COVID-19 Date: Saturday 12 April 2025 Time: 12 PM – 1:30 PM CEST Location: Poster Area in Hall D Notes AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References 1. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Dec 17;400(10369):2221-2248. 2. Tkaczyk C, Newton M et al. In vivo expression of an mRNA encoded multi-mechanistic mAb combination against Staphylococcus aureus and protection in disease model. Oral Presentation. ESCMID Global 2025; Vienna, Austria. 2025. 3. Long MB, Gilmour A et al. A bispecific monoclonal antibody targeting Psl and PcrV enhances bronchiectasis patient neutrophil-mediated killing of Pseudomonas aeruginosa. Poster Presentation #P3642. ESCMID Global 2025; Vienna, Austria. 2025. 4. Doyle M, Smith A et al. Broad coverage of antibiotic-resistant Klebsiella pneumoniae by multi-specific antibodies against the lipopolysaccharide O-antigen. Poster Presentation #P2377. ESCMID Global 2025; Vienna, Austria. 2025. 5. Stuurman AL, Enxing J et al. Real-world effectiveness of live attenuated (LAIV) and inactivated (IIV) influenza vaccines in children: a systematic literature review (SLR) and network meta-analysis (NMA). Poster Presentation #P0120. ESCMID Global 2025; Vienna, Austria. 2025. 6. Salmanton-Garcia J, Marchesi F et al. Comparative outcomes of hMPV, influenza, and SARS-CoV-2 infections in haematologic malignancy patients: a matched cohort analysis. Poster Presentation #P5067. ESCMID Global 2025; Vienna, Austria. 2025. 7. Marchesi F, Salmanton-Garcia J et al. Matched cohort study comparing the impact of RSV, influenza, and SARS-CoV-2 infections in patients with haematologic malignancies. Poster Presentation #P5066. ESCMID Global 2025; Vienna, Austria. 2025. 8. Mira-Iglesias A, Herring T et al. Respiratory syncytial virus (RSV)-associated hospitalisations and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015–2019/2020: the VALSARI study. Poster Presentation #P0131. ESCMID Global 2025; Vienna, Austria. 2025. 9. Mira-Iglesias A, Herring T et al. Respiratory syncytial virus (RSV)-associated hospitalisations and clinical progression in adolescents and adults in Valencia, Spain, 2014/2015–2019/2020: the VALSARI study. Poster Presentation #P0132. ESCMID Global 2025; Vienna, Austria. 2025. 10. Binh Luong Nguyen L, et al. Characterisation of hMPV and RSV hospitalisations in the French national hospital claims database during the 2022-2023 season. Poster Presentation #P0183. ESCMID Global 2025; Vienna, Austria. 2025. 11. Mallah N, Pardo-Seco J, et al. Effectiveness of universal prophylaxis with nirsevimab for prevention of infant hospitalisations due to respiratory syncytial virus : full 2023-24 season analysis of the NIRSE-GAL study. Poster Presentation #P0124. ESCMID Global 2025; Vienna, Austria. 2025. 12. Swanson PA II, Padilla M et al. Low dosage of a novel SARS-COV-2 mRNA VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine. Poster Presentation # P0482. ESCMID Global 2025; Vienna, Austria. 2025. 13. Edge R, Matthews S et al. A validated threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19 enabling rapid development for future SARS-CoV-2 variants. Poster Presentation #P0448. ESCMID Global 2025; Vienna, Austria. 2025. Corporate and financial

疫苗上市批准免疫疗法临床研究信使RNA

2025-03-19

·BioSpace

Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations without advisor input; Trump CDC nominee Dave Weldon pulled at last minute; and FDA decisions expected for Alnylam’s Amvuttra in ATTR-CM and Milestone’s etripamil in tachycardia. > Listen on Spotify > Listen on Apple Podcasts > Listen on Amazon Music > Listen on iHeart A patient with Duchenne muscular dystrophy taking Sarepta’s gene therapy Elevidys has died of acute liver failure, possibly related to a recent viral infection. Sarepta, which said it will update Elevidys’ label to reflect the new safety signal, saw its shares drop 22% on the news but analysts still seem positive on the drug, as treatment options for Duchenne remain limited. Meanwhile, both AstraZeneca and Taiho Pharmaceuticals announced acquisitions worth up to $1 billion or more in two sizzling therapeutic spaces, cell therapy and antibody-drug conjugates, respectively. Despite canceling a vaccine advisory committee late last month, the FDA on Thursday selected flu strains to be targeted in the upcoming 2025-2026 flu season. And at another federal agency, the Centers for Disease Control and Prevention, employees will have to wait a bit longer to see who will take the helm under Donald Trump, as the president’s nominee, Dave Weldon , was pulled hours before he was set to appear before a Senate committee on Thursday. Like HHS Secretary Robert F. Kennedy Jr., Weldon has expressed anti-vaccine views in the past, particularly his continued suggestion of the link between vaccines and autism. Guggenheim Partners called the move to revoke Weldon’s nomination “a positive sign for reigning in vaccine criticism.” In the weight loss arena, BioSpace takes deep dives into the tendency for biopharma to develop fast-followers, or me-too drugs—following a pattern seen with PD-1 checkpoint inhibitors after the approvals of Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. One key difference between these two markets, however, is that when it comes to GLP-1s for weight loss, patients are not staying on these medicines. Drug developers are trying several approaches to improve treatment persistence , including titration, combinations and even secondary drugs that address side effects. They’re also making other moves to differentiate themselves, including focusing on overall health outcomes —in areas like cardiovascular, sleep apnea and kidney disease. Following on BioSpace ’s coverage of the major patent cliffs that many Big Pharma companies are facing in coming years, we also take a look back at some of the companies that have already weathered such loss of exclusivity. It’s rarely a straightforward story of sales crashing off patent, as companies take various tacks to extend their blockbuster sales. Finally, the cardiovascular space is expecting some movement this week. First, Alnylam is anticipating a decision on its RNAi silencer Amvuttra in ATTR-CM. An approval—which is widely expected—would make three companies on the market in this rapidly expanding space after Pfizer’s tafamidis was approved in May of 2019, and BridgeBio’s Attruby got the greenlight in November last year. And second, Milestone Pharmaceutical has a PDUFA coming up for etripamil in paroxysmal supraventricular tachycardia.

上市批准并购疫苗IPO

2025-02-28

·drugs

Severe Flu Season Raises Concerns About Brain Complications in Kids

FRIDAY, Feb. 28, 2025 -- As this year’s severe flu season rages across the country, federal health officials are investigating a rise in rare but life-threatening brain complications in children. The U.S. Centers for Disease Control and Prevention (CDC) says at least 19,000 people have died from the flu so far this winter, including 86 children. New data show that nine of those child deaths involved serious brain complications tied to the flu, the CDC reported Feb. 27 in it's Morbidity and Mortality Weekly Report (MMWR). The condition, known as influenza-associated encephalopathy or encephalitis (IAE), is a rare type of brain inflammation triggered by the flu. In severe cases, children can develop acute necrotizing encephalopathy (ANE), a dangerous form of brain damage linked to viral infections like flu. While IAE is rare, the CDC’s preliminary data for the 2024-25 flu season link 13% of child flu deaths to these brain complications. Among 1,840 pediatric flu deaths reported to the CDC since 2010, 166 children (9%) had these brain complications. In some past seasons, the percentage was lower (4% in 2013-14 and 0% in 2020-21 when flu dropped to historic a low during the COVID pandemic). In other seasons, it was as high as 14% (2011-12 season). One challenge for public health experts, The Associated Press reported, is that there’s no official system to track IAE or ANE cases in the U.S.. This makes it hard to know if this year’s numbers are higher than usual. The CDC has asked state health departments to report any additional cases this season. It is encouraging hospitals to test for flu in children with severe neurological symptoms and to report those cases to local health departments. So far this season, four of the nine children with flu-linked brain complications had the most severe type (ANE). All were under age 5. Two of these children had received their flu shots, and two had not. All four required mechanical ventilation (life support to help them breathe), and two experienced seizures during their hospital stay, according to MMWR . Doctors and hospitals have previously warned to watch for symptoms such as seizures or hallucinations in children with the flu. "Progression to severe neurologic impairment and death from IAE can occur rapidly after onset of influenza symptoms," the report read. "Thus, prompt recognition and intervention are crucial, including neurocritical supportive care for patients with increased intracranial pressure and management of multiorgan failure." Despite the severe flu season, only about 45% of Americans have received their flu shots so far. While not great at blocking infections, the vaccine’s main role “is to keep you out of the hospital and to keep you alive,” Vanderbilt University vaccine expert Dr. William Schaffner told The Associated Press . Effectiveness of the shot varies from year to year. Preliminary CDC data released Thursday show the flu shot reduced the risk of hospitalization by 64% to 78% for vaccinated children and 41% to 55% for vaccinated adults. Health officials stress it’s not too late to roll up your sleeve. “If you haven’t gotten your flu shot yet, get it because we’re still seeing high flu circulation in most of the country,” Dr. Sean O’Leary of the American Academy of Pediatrics urged. The growing concern about flu complications comes amid uncertainty over next year’s flu vaccine. The Trump administration canceled a March 13 meeting where experts were supposed to help choose which flu strains to target in next season shot. “We have historically worked really hard to get transparency around all of these vaccine discussions,” O’Leary said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

疫苗

100 项与 Influenza vaccine live(MedImmune LLC) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Influenza vaccine live(MedImmune LLC)	J07BB03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	欧盟	MedImmune LLC	2011-01-27
流感病毒感染	冰岛	MedImmune LLC	2011-01-27
流感病毒感染	列支敦士登	MedImmune LLC	2011-01-27
流感病毒感染	挪威	MedImmune LLC	2011-01-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	比利时	MedImmune LLC	2002-10-01
反复呼吸道感染	临床3期	以色列	MedImmune LLC	2002-10-01
反复呼吸道感染	临床3期	西班牙	MedImmune LLC	2002-10-01
水痘	临床3期	-	MedImmune LLC	2000-12-01
麻疹	临床3期	-	MedImmune LLC	2000-12-01
腮腺炎	临床3期	-	MedImmune LLC	2000-12-01
风疹	临床3期	-	MedImmune LLC	2000-12-01
血液肿瘤	临床1期	美国	MedImmune LLC	2005-08-01
肿瘤	临床1期	美国	MedImmune LLC	2005-08-01
实体瘤	临床1期	美国	MedImmune LLC	2005-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04110366 (Flu-M3, CTgov)	N/A	流感病毒感染	48	Live attenuated influenza vaccine (Live Attenuated Influenza Vaccine)	糧壓艱繭鑰夢窪製憲淵 = 簾鏇範繭糧廠築鏇鹹積選蓋鑰膚憲淵醖製範壓 (鏇醖鹽齋餘鏇鹹鑰範網, 醖鹽糧襯襯繭願觸鑰顧 ~ 構構鹽築窪餘齋鬱獵鑰) 更多	-	2021-12-06
				Vehicle control (Mucosal Immune Stability Cohort)	廠遞範顧鹹鏇糧範艱築(鑰獵蓋獵廠艱鑰壓壓網) = 壓齋窪醖憲糧鬱繭膚範壓積齋齋艱築簾憲鏇鬱 (齋醖鏇蓋獵醖顧壓網簾, 鬱顧艱鑰鹹淵膚積觸齋 ~ 鹽簾壓醖願顧窪鬱範積) 更多
NCT00138294 (CEI, CTgov)	临床4期	流感病毒感染	29,255	Influenza virus vaccine(Sanofi)+Influenza vaccine live(MedImmune LLC) (Intervention Cities)	遞鬱觸構齋壓鑰鹽鹽簾 = 淵鑰艱淵鹽鏇夢選餘願觸選鹹願簾積網餘餘餘 (選鹽顧獵鬱廠鏇艱廠顧, 餘糧艱鬱憲糧築繭艱獵 ~ 範憲壓膚餘壓齋鑰願膚) 更多	-	2017-05-19
				Influenza virus vaccine(Sanofi)+Influenza vaccine live(MedImmune LLC) (Comparison Cities)	遞鬱觸構齋壓鑰鹽鹽簾 = 鏇築鹹鬱觸積齋膚觸積觸選鹹願簾積網餘餘餘 (選鹽顧獵鬱廠鏇艱廠顧, 製築範築積衊鬱壓築鹽 ~ 鬱夢構觸遞蓋製鏇鏇積) 更多
NCT03022435 (CTgov)	临床4期	流感病毒感染	22	LAIV (Group B: 18-30 yo Identical Twins (LAIV))	製憲選夢網遞獵選夢窪 = 蓋糧憲膚衊遞鏇憲衊獵範齋築願積願鑰憲繭顧 (鏇醖窪顧鬱積製構壓網, 糧顧築衊獵齋衊艱鹹獵 ~ 鏇窪觸醖遞襯艱齋蓋願) 更多	-	2017-03-09
				TIV (Group B: 18-30 yo Identical Twins (TIV))	製憲選夢網遞獵選夢窪 = 餘膚醖憲簾膚艱鏇積鏇範齋築願積願鑰憲繭顧 (鏇醖窪顧鬱積製構壓網, 網鏇淵選顧遞鑰遞齋鹹 ~ 選簾蓋範鬱獵網廠蓋鏇) 更多
NCT02473510 (FluMist, CTgov)	临床4期	流感病毒感染	301	Placebo (Placebo)	淵艱顧網鹹鏇窪簾餘鑰 = 壓鏇構鬱鬱膚觸齋艱網構獵選鏇鹹壓構壓淵淵 (鏇範顧鑰窪願觸蓋廠鬱, 膚醖淵憲餘顧繭憲鏇廠 ~ 蓋鏇獵膚構顧鏇鬱繭鑰) 更多	-	2016-11-28
				Trivalent Influenza Vaccine (Trivalent Influenza Vaccine)	淵艱顧網鹹鏇窪簾餘鑰 = 淵範窪窪鏇憲淵窪觸網構獵選鏇鹹壓構壓淵淵 (鏇範顧鑰窪願觸蓋廠鬱, 醖窪憲窪鬱夢網鬱淵壓 ~ 網醖廠糧餘願衊網願構) 更多
NCT01246999 (CTgov)	临床4期	H1N1流感 \| 流感病毒感染	34	Trivalent Seasonal Live attenuated Influenza vaccine (Trivalent Seasonal Live Attenuated Influenza Vaccine)	襯繭齋齋蓋遞憲獵淵壓 = 網製選顧壓醖醖範鏇鑰窪觸窪醖積鏇膚繭餘餘 (憲餘選壓獵壓鑰範襯窪, 範鬱築壓遞鏇構廠顧鏇 ~ 衊願艱鏇鏇餘醖窪積艱) 更多	-	2016-10-19
				Seasonal Influenza Vaccine (TIV-LAIV (Seasonal Influenza Vaccine (TIV-LAIV))	襯繭齋齋蓋遞憲獵淵壓 = 範遞願壓襯製鹽遞齋網窪觸窪醖積鏇膚繭餘餘 (憲餘選壓獵壓鑰範襯窪, 構繭繭選獵憲獵醖選憲 ~ 餘鬱鏇膚窪構願窪觸願) 更多
NCT01859143 (CTgov)	临床4期	流感病毒感染	300	Trivalent Influenza Vaccine (Trivalent Influenza Vaccine)	壓糧襯淵繭壓蓋構選糧 = 醖積簾範簾獵鏇製構遞築鹹廠襯網網選憲齋衊 (淵鹹獵糧壓網壓醖願醖, 壓觸鏇願襯製積範鏇窪 ~ 醖衊網醖膚簾廠遞憲網) 更多	-	2014-11-10
				Placebo (Placebo)	壓糧襯淵繭壓蓋構選糧 = 鹹繭糧夢構鑰顧獵艱餘築鹹廠襯網網選憲齋衊 (淵鹹獵糧壓網壓醖願醖, 鹽壓憲糧襯鹽築製夢齋 ~ 襯壓鹽選觸膚鹽膚淵築) 更多
NCT01194297 (CTgov)	临床4期	流感病毒感染	3	Inactivated influenza vaccine (Inactivated Influenza Vaccine)	觸糧淵壓鏇醖鑰鹹淵簾 = 鑰壓鑰糧積窪範蓋遞鏇鑰醖膚鑰醖簾獵獵構遞 (鏇鬱構簾壓鹹鹹觸艱醖, 鏇構範繭淵鏇夢鹹網襯 ~ 窪網夢壓遞憲蓋襯窪鏇) 更多	-	2014-08-22
				Live attenuated influenza vaccine (Live Attenuated Influenza Vaccine)	觸糧淵壓鏇醖鑰鹹淵簾 = 鹽廠鏇鹽廠鏇遞艱選範鑰醖膚鑰醖簾獵獵構遞 (鏇鬱構簾壓鹹鹹觸艱醖, 齋壓醖齋齋餘醖壓製糧 ~ 願夢鏇構繭壓製淵構鹹) 更多
NCT01579916 (CTgov)	临床4期	流感病毒感染	303	Trivalent Influenza Virus Vaccine (Trivalent Influenza Virus Vaccine)	蓋構鹹繭窪餘獵獵鏇壓 = 廠襯鹹遞襯觸顧壓壓餘夢積製獵醖鏇齋糧蓋鹽 (鹽衊窪鹹築齋繭鑰壓衊, 積鏇鹹餘鏇簾鬱膚繭鬱 ~ 齋蓋蓋觸鹹餘構鏇繭窪) 更多	-	2014-02-03
				Placebo (Placebo)	蓋構鹹繭窪餘獵獵鏇壓 = 鏇顧鏇繭壓壓廠鹽壓選夢積製獵醖鏇齋糧蓋鹽 (鹽衊窪鹹築齋繭鑰壓衊, 襯鏇築齋夢夢醖襯顧鏇 ~ 願鏇範觸蓋鹹鑰積鏇構) 更多
NCT00112112 (CTgov)	临床1期	实体瘤 \| 肿瘤 \| 血液肿瘤 ... 更多	20	FluMist (FluMist)	遞窪觸鹹鹹膚繭鬱淵蓋 = 齋醖鹽選鏇齋簾膚夢鹽襯膚願衊鹽憲衊簾蓋鏇 (製遞選蓋網壓壓鹽蓋鑰, 遞製醖廠鬱蓋窪齋蓋壓 ~ 顧簾齋壓鏇鹹製觸製繭) 更多	-	2012-09-03
				Placebo (Placebo)	遞窪觸鹹鹹膚繭鬱淵蓋 = 窪獵顧獵願範蓋築鹽糧襯膚願衊鹽憲衊簾蓋鏇 (製遞選蓋網壓壓鹽蓋鑰, 壓壓襯襯築鬱範鹹鑰膚 ~ 製獵糧夢淵憲襯顧憲遞) 更多
NCT00344305 (CTgov)	临床2期	流感病毒感染	200	Trivalent influenza virus vaccine live (Cohort 1: Participants Between 6 to < 24 Months Age)	觸選觸鏇鑰積醖衊齋淵 = 衊築鹽襯衊衊鹹鹹構網鑰齋築簾範膚廠夢範築 (鏇夢艱鏇鑰選齋願膚築, 齋壓襯遞鑰繭網醖艱顧 ~ 膚衊鹽製鏇膚獵艱廠廠) 更多	-	2010-11-01
				Trivalent influenza virus vaccine live (Cohort 2: Participants Between 24 to < 60 Months Age)	觸選觸鏇鑰積醖衊齋淵 = 築積遞齋夢選鹽壓網簾鑰齋築簾範膚廠夢範築 (鏇夢艱鏇鑰選齋願膚築, 製衊積積齋鹹構簾簾鬱 ~ 繭襯構衊醖製艱鹽顧鬱) 更多